Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company specializing in brain-targeted therapeutics, has announced its targeted milestones for 2026 as it advances ONP-002, an intranasal neurosteroid, toward Phase 2 clinical development. The company is preparing to initiate a Phase 2a clinical trial in Australia for the treatment of concussion and mild traumatic brain injury (mTBI). This positions ONP-002 as a potential first-in-class pharmacological therapy for a significant and underserved global market, following positive preclinical and Phase 1 safety and efficacy results.
Concussion and mTBI affect millions worldwide each year, yet there are no approved pharmacological treatments specifically for these conditions. Oragenics' intranasal delivery platform offers a novel approach, allowing direct brain targeting and potentially rapid onset of action. The progression of ONP-002 into Phase 2a trials marks a critical step in addressing this unmet medical need, with implications for athletes, military personnel, and the general population at risk of head injuries.
The company's intranasal delivery technology has broader applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet needs in neurological care. The Phase 2a trial in Australia is designed to evaluate the efficacy and safety of ONP-002 in patients with concussion, with U.S. Phase IIb trials planned to follow.
For more details on the press release, visit this link. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.
The announcement underscores the potential of Oragenics' pipeline and delivery platform, which could transform the treatment landscape for concussion and other neurological disorders. With no approved pharmacological therapies currently available, a successful Phase 2a trial would represent a major advancement in concussion management.
